Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model

Pathology

Volumn 31, Issue 3, 1999, Pages 264-267

  Ulett, Glen C ^a   Norton, Robert E ^b   Hirst, Robert G ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

BALB c; Burkholderia pseudomallei; Cefpirome; Ceftazidime; Melioidosis; Mouse model

Indexed keywords

ANTIBIOTIC AGENT; CEFPIROME; CEFTAZIDIME; CHLORAMPHENICOL; COTRIMOXAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MELIOIDOSIS; MOUSE; NONHUMAN;

EID: 0032873958     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/003130299105106     Document Type: Article

References (18)

1. Dance DAB. Melioidosis: the Tip of the Iceberg? Clin Microbiol Rev 1991; 4: 52-60.
2. Hirst RG, Indriana J, Cocciolone RA. An introduction to melioidosis. Innate resistance and acquired immunity to Pseudomonas pseudomallei. Aust Biol 1992; 5(4): 203-13.
3. Norton R, Roberts B, Freeman M, et al. Characterisation and molecular typing of Burkholderia pseudomallei: are disease presentations of melioidosis clonally related? FEMS Immunol Med Microbiol 1998; 20: 37-44.
4. Leakey AK, Ulett GC, Hirst RG. BALB/c and C57BL/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animals models for the acute and chronic forms of human melioidosis. Microbiol Pathol 1998; 24: 269-75.
5. Smith CJ, Allen JC, Noor Embi M, et al. Human Melioidosis: an emerging medical problem. MIRCEN J 1987; 3: 343-66.
6. Chaowagul W, Suputtamongkol Y, Dance DAB, et al. Relapse in melioidosis: incidence and risk factors. J Infect Dis 1993; 168: 1181-5.
7. Tan AL, Ang BSP, Ong YY. Meliodosis: epidemiology and antibiogram of cases in Singapore. Singapore Med J 1990; 31: 335-7.
8. White NJ, Dance DAB, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2: 697-701.
9. Chaowagul W. Recent advances in treatment of severe melioidosis. International Congress on Melioidosis: State of the Art Discoveries and Trends towards the 21st Century, Program and Abstracts Booklet. 1998; PL2: 22.
10. Dance DAB, Wuthiekanun V, Chaowagul W, et al. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 1989; 24: 295-309.
11. Dance DAB, Wuthiekanun V, Chaowagul W, et al. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. J Antimicrob Chemother 1991; 28: 321-4.
12. Seymour-Murray J, Norton R, Ashhurst-Smith C. Comparative in vitro susceptibility of Burkholderia pseudomallei to cefpirome, ceftazidime and cefepime. Pathology 1997; 29: 329-30.
13. Puthucheary SD, Parasakthi N. Susceptibility of 57 strains of Ps. pseudomallei to some newer B-lactams and other antibiotics. Med J Malaysia 1987; 42(4): 248-51.
14. Ulett GC, Ketheesan N, Hirst RG. Macrophage-lymphocyte interactions mediate anti-Burkholderia pseudomallei activity. FEMS Immunol Med Microbiol 1998; 21: 283-6.
15. Balows A. Manual of Clinical Microbiology. Chapter III, Susceptibility Tests: Diffusion Test Procedures. Washington, DC: DNLM/DLC, 1991.
16. Performance Standards for antimicrobial susceptibility testing. National Committee for Clinical Laboratory Standards. In: NCCLS M100-S6. 1995; 15 (14).
17. Brody S. Bioenergetics and Growth. Chapter 13, Basal Energy and Protein Metabolism in Relation to Body Weight in Mature Animals of Different Species. New York: Hafner Press; 1974.
18. Howe C, Sampath A, Spotnitz M. The pseudomallei group: a review. J Infect Dis 1971; 124(6): 598-606.